TFX REMINDER: Teleflex Incorporated is Being Investigated for Securities Fraud; Shareholders are Alerted to Contact BFA Law (NYSE:TFX)

Core Viewpoint - Teleflex Incorporated is under investigation for potential violations of federal securities laws following significant corporate announcements, including a business split and a major acquisition [1][2][3]. Group 1: Company Announcements - On February 27, 2025, Teleflex announced the separation of its Urology, Acute Care, and OEM businesses into a new publicly traded company [2]. - The company also reported the resignation of its CFO and plans to acquire the vascular intervention business of BIOTRONIK SE for approximately €760 million [2]. Group 2: Investigation Details - Bleichmar Fonti & Auld LLP is investigating whether Teleflex and certain senior officers made materially false and misleading statements to investors, given the company's previous positive representations [3]. - The investigation follows the company's recent announcements, which have raised concerns about the accuracy of prior communications to investors [3]. Group 3: Market Reaction - Following the announcements on February 27, 2025, Teleflex's stock price experienced a decline of approximately 20% during trading [4].